Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease.

Literature DB >> 20439608

Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease.

José Moltó¹, José Sanz-Moreno, Marta Valle, Samandhy Cedeño, Jordi Bonal, Hanane Bouarich, Bonaventura Clotet.

Abstract

Little is known about raltegravir removal by hemodialysis in patients with end-stage renal disease (ESRD). We therefore measured raltegravir concentrations in plasma in pre- and postdialyzer blood samples from 2 ESRD HIV-infected patients. The hemodialysis extraction ratio and raltegravir hemodialysis clearance were 5.5% and 9.1 ml/min in patient 1 and 9.5% and 19.1 ml/min in patient 2, respectively. Our results suggest minimal raltegravir removal by hemodialysis with no specific raltegravir dosage adjustments required in HIV-infected patients undergoing hemodialysis.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2010 PMID： 20439608 PMCID： PMC2897307 DOI： 10.1128/AAC.00363-10

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

8 in total

1. Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on haemodialysis.

Authors: Pierre Giguère; Charles la Porte; Guijun Zhang; Bill Cameron
Journal: AIDS Date: 2009-03-27 Impact factor: 4.177

2. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease.

Authors: Elissa J Schwartz; Lynda A Szczech; Michael J Ross; Mary E Klotman; Jonathan A Winston; Paul E Klotman
Journal: J Am Soc Nephrol Date: 2005-06-29 Impact factor: 10.121

3. Quantitative prediction of human clearance guiding the development of Raltegravir (MK-0518, isentress) and related HIV integrase inhibitors.

Authors: Ralph Laufer; Odalys Gonzalez Paz; Annalise Di Marco; Fabio Bonelli; Edith Monteagudo; Vincenzo Summa; Michael Rowley
Journal: Drug Metab Dispos Date: 2009-01-14 Impact factor: 3.922

4. Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors.

Authors: Chioma Pedro Emem; Fatiu Arogundade; Abubakr Sanusi; Kayode Adelusola; Friday Wokoma; Adewale Akinsola
Journal: Nephrol Dial Transplant Date: 2007-12-08 Impact factor: 5.992

5. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

Authors: Jeffrey L Lennox; Edwin DeJesus; Adriano Lazzarin; Richard B Pollard; Jose Valdez Ramalho Madruga; Daniel S Berger; Jing Zhao; Xia Xu; Angela Williams-Diaz; Anthony J Rodgers; Richard J O Barnard; Michael D Miller; Mark J DiNubile; Bach-Yen Nguyen; Randi Leavitt; Peter Sklar
Journal: Lancet Date: 2009-08-03 Impact factor: 79.321

6. Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection.

Authors: Jean-Marie Poirier; Pascal Robidou; Patrice Jaillon
Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2008-04-04 Impact factor: 3.205

7. Raltegravir with optimized background therapy for resistant HIV-1 infection.

Authors: Roy T Steigbigel; David A Cooper; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey L Lennox; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Bach-Yen Nguyen; Hedy Teppler
Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245

8. Chronic renal failure among HIV-1-infected patients.

Authors: Amanda Mocroft; Ole Kirk; Jose Gatell; Peter Reiss; Panagiotis Gargalianos; Kai Zilmer; Marek Beniowski; Jean-Paul Viard; Schlomo Staszewski; Jens D Lundgren
Journal: AIDS Date: 2007-05-31 Impact factor: 4.177

8 in total

7 in total

7. Selective and rapid determination of raltegravir in human plasma by liquid chromatography-tandem mass spectrometry in the negative ionization mode.

Authors: Ajay Gupta; Swati Guttikar; Priyanka A Shah; Gajendra Solanki; Pranav S Shrivastav; Mallika Sanyal
Journal: J Pharm Anal Date: 2014-10-23

7 in total

Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease.

1. Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on haemodialysis.

2. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease.

3. Quantitative prediction of human clearance guiding the development of Raltegravir (MK-0518, isentress) and related HIV integrase inhibitors.

4. Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors.

5. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

6. Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection.

7. Raltegravir with optimized background therapy for resistant HIV-1 infection.

8. Chronic renal failure among HIV-1-infected patients.

Review 1. Renal disease in HIV-infected individuals.

2. HIV and HCV Medications in End-Stage Renal Disease.

Review 3. Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.

Review 4. Renal effects of novel antiretroviral drugs.

Review 5. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.

6. Role of raltegravir in the management of HIV-1 infection.

7. Selective and rapid determination of raltegravir in human plasma by liquid chromatography-tandem mass spectrometry in the negative ionization mode.